A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

New England Journal of Medicine

Volumn 349, Issue 21, 2003, Pages 2004-2013

  Lebwohl, Mark ^a   Tyring, Stephen K ^b   Hamilton, Tiffani K ^c   Toth, Darryl ^d   Glazer, Scott ⁱ   Tawfik, Naji H ^e   Walicke, Patricia ^f   Dummer, Wolfgang ^f   Wang, Xiaolin ^f   Garovoy, Marvin R ^g   Pariser, David ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Vein and Research Center LLC   (United States)

^d Probity Medical Research   (Canada)

^e Welborn Baptist Hospital   (United States)

^f GENENTECH INC   (United States)

^g XOMA   (United States)

^h EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

ⁱ Box 1048 ^*

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB;

ADULT; AGED; ARTHRITIS; ARTICLE; BODY WEIGHT; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEVER; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS; SIDE EFFECT; T LYMPHOCYTE; TARGET CELL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 0345107256     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030002     Document Type: Article

References (27)

1. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
3. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61:Suppl:11-21.
4. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000;43:S43-S46.
5. Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - short- and long-term toxicity in 104 patients. Clin Rheumatol 2001;20:406-10.
6. Grossman KM, Chevret S, Abi-Kached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132;623-9.
7. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61.
8. Bos JD, Hulsebosch HJ, Krieg SP, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis: in situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-9.
9. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
10. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999;285:221-7.
11. Kuypers TW, Roos D. Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. Res Immunol 1989;140:461-86.
12. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-31.
13. Werther WA, Gonzalez TN, O'Connor SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986-95.
14. Krueger GG. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther 2002;2:431-41.
15. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000;115:333.
16. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.
17. Papp K, Bissonnette K, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001;45:665-74.
18. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke P, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
19. Wei LJ, Lachin J. Properties of the urn randomization in clinical trials. Control Clin Trials 1988;9:345-64. [Erratum, Control Clin Trials 1989;10:126a.]
20. Wei LJ, Lachin J. Properties of the urn randomization in clinical trials. Control Clin Trials 1988;9:345-64. [Erratum, Control Clin Trials 1989;10:126a.]
21. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CEM. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185-91.
22. Gottlieb AB. Psoriasis. Dis Manag Clin Outcomes 1998;1:195-202.
23. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
24. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
25. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
26. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
27. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.